The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers.

Pascale A Cohen,Susan Fineberg,Olivier Loudig,Joseph Albanese,Christina Liu

doi:10.3389/fphar.2019.00524

Abstract

We assessed mRNA and protein expression levels of the ZN217 oncogene in 17 clinical FFPE ER-positive invasive breast cancer specimens with known (low or high) Oncotype DX® Recurrence Scores. This study shows that mRNA or nuclear protein levels of the ZNF217 significantly correlate with Oncotype DX® Recurrence Score.

Highlights

Reviewed by: Massimo Libra, Università degli Studi di Catania, Italy Massimiliano Berretta, Centro di Riferimento Oncologico di Aviano (IRCCS), Italy
This study shows that mRNA or nuclear protein levels of the ZNF217 significantly correlate with Oncotype DX® Recurrence Score
The Oncotype DX R (ODX) genomic assay tests for the expression of 21 genes and calculates a Recurrence Score (RS), which predicts the risk of distant disease recurrence in ER+ Breast cancer (BC)

Summary

Introduction

Reviewed by: Massimo Libra, Università degli Studi di Catania, Italy Massimiliano Berretta, Centro di Riferimento Oncologico di Aviano (IRCCS), Italy. We assessed mRNA and protein expression levels of the ZN217 oncogene in 17 clinical FFPE ER-positive invasive breast cancer specimens with known (low or high) Oncotype DX® Recurrence Scores. This study shows that mRNA or nuclear protein levels of the ZNF217 significantly correlate with Oncotype DX® Recurrence Score.

Results

Conclusion